ERYtech Pharma is a biopharmaceutical company, develops enzyme-based medicinal products for the oncology, hematology and immunology sectors.
Erytech’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Encapsulation offers a number of benefits as compared to free-form compounds, reducing the potential for allergic reactions and allowing the therapeutic substance to remain longer in the body.
ERYtech Pharma was founded in 2004 & is based in Lyon, Rhone-Alpes, France.
ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.
Erytech's lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells.
Erytech is venture backed by investors such as Auriga Partners, Ardian, Idinvest Partners, Amorçage Rhône Alpes etc. The company went public on Nov 9, 2017, and raised $125M at IPO with a Valuation of $398M.